Over roughly the past week, formal NITAG/agency outputs have largely reinforced and operationalized earlier 2026 policy decisions, while the most clearly “new” developments sit in World/Regional Immunization Week campaigns, a fresh NITAG roundup, and significant manufacturer milestones, notably Moderna’s H5 pandemic influenza phase 3 and EU approval of its flu–COVID combination vaccine. Over roughly the past week, formal NITAG/agency outputs have largely reinforced and operationalized earlier 2026 policy decisions, while the most clearly “new” developments sit in World/Regional Immunization Week campaigns, a fresh NITAG roundup, and significant manufacturer milestones, notably Moderna’s H5 pandemic influenza phase 3 and EU approval of its flu–COVID combination vaccine. Global framing World Immunization Week 2026 (24–30 April) is underway with the WHO theme “For every generation, vaccines work,” emphasizing life‑course immunization and confidence‑building messaging. (WHO). WHO, NCIRS and others are explicitly using the week to highlight recovery of routine coverage, with WHO and UNICEF communications citing the contribution...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
